← Back to Search

Nonsteroidal Anti-inflammatory Drug

SULT Allosteric Inhibition for Metabolic Side Effects

Phase < 1
Waitlist Available
Led By Thomas S Leyh, Ph. D.
Research Sponsored by Albert Einstein College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gender - one male
Age - 61 y.o.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15min, 30min, 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr, 9hr, 10hr, 11hr, and 12hr following administration.
Awards & highlights

Study Summary

This trial will test whether the NSAID mefenamic acid can inhibit the sulfonation of the specific substrate acetaminophen in humans, and whether this effect is specific to SULT1A1 or whether it is also seen with SULT2A1.

Eligible Conditions
  • Metabolic Side Effects

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15min, 30min, 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr, 9hr, 10hr, 11hr, and 12hr following administration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15min, 30min, 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr, 9hr, 10hr, 11hr, and 12hr following administration. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Prasterone

Trial Design

1Treatment groups
Experimental Treatment
Group I: SULT Allosteric InhibitionExperimental Treatment1 Intervention
A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SULT Allosteric Inhibition
2018
Completed Early Phase 1
~10

Find a Location

Who is running the clinical trial?

Albert Einstein College of MedicineLead Sponsor
285 Previous Clinical Trials
11,854,641 Total Patients Enrolled
Thomas S Leyh, Ph. D.Principal InvestigatorThe Albert Einstein College of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals aged 50 or over permitted to participate in this experiment?

"Patients aged 61 to 65 are eligible for participation in this trial, while those younger than 18 and older than 65 have access to 8 and 40 trials respectively."

Answered by AI

What eligibility criteria must be fulfilled to join this experimental trial?

"This research is accepting one individual, aged 61 years old, who displays metabolic side effects of medications as a participant. Moreover, the candidate must meet all other criteria listed in the inclusion requirements."

Answered by AI

Does this trial currently have available spots for participants?

"The trial listed on clinicaltrials.gov is not actively enrolling patients, with the first posting being made in November 2018 and most recent update occurring in April 2022. Fortunately, there are 44 other trials presently recruiting candidates for participation."

Answered by AI
Recent research and studies
~0 spots leftby Mar 2025